Metabolic vulnerabilities in endometrial cancer

Area of Science:

• Oncology
• Cancer Metabolism
• Biochemistry

Background:

• Metabolic disorders like obesity and diabetes increase endometrial cancer risk.
• Endometrial tumor metabolism remains understudied.
• Identifying key metabolic drivers is crucial for therapeutic development.

Purpose of the Study:

• To investigate the metabolic alterations in endometrial tumors.
• To identify novel therapeutic targets in endometrial cancer.
• To evaluate the efficacy of targeting cancer metabolism.

Main Methods:

• Comparative analysis of human endometrial tumors and cells versus nonmalignant counterparts.
• Gene expression analysis focusing on glucose transporters and glycolytic enzymes.
• Functional studies involving GLUT6 suppression.
• Compound screening targeting metabolic pathways.
• In vitro and in vivo xenograft models.

Main Results:

• Upregulation of glucose transporter GLUT6 is strongly associated with the endometrial cancer phenotype.
• Suppression of GLUT6 inhibits glycolysis and cancer cell survival.
• Glycolysis and lipogenesis are coupled with the cancer phenotype.
• 3-bromopyruvate inhibits lipogenesis and promotes necrotic cell death.
• 3-bromopyruvate impairs endometrial cancer xenograft growth.

Conclusions:

• GLUT6 is a critical regulator of endometrial cancer cell metabolism and survival.
• Targeting cancer metabolism, specifically glycolysis and lipogenesis, is a viable therapeutic strategy.
• 3-bromopyruvate demonstrates potent anti-cancer effects in endometrial cancer models.